Pediatric myelodysplastic syndromes: They do exist!

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 1, 2014, Pages 1-7

  Glaubach, Taly ^a   Robinson, Lisa J ^b   Corey, Seth J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aplastic anemia; Bone marrow failure syndromes; Myelodysplastic syndromes; Myeloid leukemia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT DISEASE; ANEMIA; APLASTIC ANEMIA; BONE MARROW BIOPSY; CEBPA GENE; CHILDHOOD DISEASE; CLINICAL FEATURE; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DNA METHYLATION; GATA2 GENE; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PEDIATRICS; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REVIEW; RUNX1 GENE; THROMBOCYTOPENIA;

EID: 84891758034     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000046     Document Type: Review

References (69)

1. Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: Incidence and predisposing conditions. Leukemia. 1995;9:1569-1572
2. Hasle H, Wadsworth LD, Massing BG, et al. A populationbased study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106:1027-1032
3. Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: A population-based study of incidence and survival. Br J Haematol. 2003;121:758-767
4. Jackson GH, Carey PJ, Cant AJ, et al. Myelodysplastic syndromes in children. Br J Haematol. 1993;84:185-186
5. Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: A study of 167 patients. Blood. 1999;93:459-466
6. Sasaki H, Manabe A, Kojima S, et al. Myelodysplastic syndrome in childhood: A retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713-1720
7. Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102:1997-2003
8. Strahm B, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: Results of the EWOG-MDS 98 study. Leukemia. 2011;25:455-462
9. Vlachos A, Rosenberg PS, Atsidaftos E, et al. Incidence of neoplasia in Diamond Blackfan anemia: A report from the Diamond Blackfan Anemia Registry. Blood. 2012;119: 3815-3819
10. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010;150:179-188
11. Dale DC, Bolyard AA, Schwinzer BG, et al. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 2006;3:220-231
12. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-Term G-CSF therapy. Blood. 2006;107:4628-4635
13. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009;23:215-231
14. Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood. 2010;115: 1519-1529
15. Narendran A, Hawkins LM, Ganjavi H, et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol. 2004;21:209-221
16. Hasle H, Clausen N, Pedersen B, et al. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet. 1995;79: 79-81
17. Maris JM, Wiersma SR, Mahgoub N, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer. 1997;79:1438-1446
18. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615
19. Ross JA, Spector LG, Robison LL, et al. Epidemiology of leukemia in children with Down syndrome. Pediatric Blood Cancer. 2005;44:8-12
20. Seif AE. Pediatric leukemia predisposition syndromes: Clues to understanding leukemogenesis. Cancer Genet. 2011;204:227-244
21. Baumann I, Fuhrer M, Behrendt S, et al. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: Reproducibility of histopathological diagnostic criteria. Histopathology. 2012;61:10-17
22. Baumann I, Niemeyer C, Führer M, et al. 378 Morphological differentiation of hypocellular refractory cytopenia of childhood and severe aplastic anemia and clinical outcome. Leukemia Res. 2011;35:S151
23. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282
24. Niemeyer CM, Baumann I. Myelodysplastic syndrome in children and adolescents. Semin Hematol. 2008;45:60-70
25. Pitman SD, Victorio A, Rowsell E, et al. 5q syndrome in a child with slowly progressive pancytopenia: A case report and review of the literature. J Pediatr Hematol Oncol. 2006;28: 115-119
26. Pui CH, Schrappe M, Ribeiro RC, et al. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004;2004:118-145
27. Stary J, Baumann I, Creutzig U, et al. Getting the numbers straight in pediatric MDS: Distribution of subtypes after exclusion of down syndrome. Pediatric Blood Cancer. 2008;50:435-436
28. Gohring G, Michalova K, Beverloo HB, et al. Complex karyotype newly defined: The strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010; 116:3766-3769
29. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64-69
30. Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599-612
31. Przychodzen B, Jerez A, Guinta K, et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood. 2013;122:999-1006
32. Hirabayashi S, Flotho C, Moetter J, et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood. 2012;119:e96-e99
33. Takita J, Yoshida K, Sanada M, et al. Novel splicing-factor mutations in juvenile myelomonocytic leukemia. Leukemia. 2012;26:1879-1881
34. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-A review. Br J Haematol. 2008;140:123-132
35. Liew E, Owen C. Familial myelodysplastic syndromes: A review of the literature. Haematologica. 2011;96:1536-1542
36. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43:1012-1017
37. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118:2653-2655
38. Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood. 2011; 118:2656-2658
39. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43:929-931
40. Baumann I, Niemeyer CM, Bennett JM, et al. Childhood myelodysplastic syndrome. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: IARC Press; 2009:104-107
41. Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica. 2006;91: 1596-1604
42. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: Further characterization of an "unclassifiable" myelodysplastic syndrome. Leukemia. 1996; 10:20-26
43. Cantu Rajnoldi A, Fenu S, Kerndrup G, et al. Evaluation of dysplastic features in myelodysplastic syndromes: Experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol. 2005; 84:429-433
44. Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia. 2007;21:668-677
45. Mueller BU, Tannenbaum S, Pizzo PA. Bone marrow aspirates and biopsies in children with human immunodeficiency virus infection. J Pediatr Hematol Oncol. 1996;18:266-271
46. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22:62-65
47. Bottom KS, Adams DM, Mann KP, et al. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Pediatr Hematol Oncol. 1997;19:73-76
48. Yetgin S, Ozen S, Saatci U, et al. Myelodysplastic features in juvenile rheumatoid arthritis. Am J Hematol. 1997;54: 166-169
49. Huff JD, Keung YK, Thakuri M, et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol. 2007;82: 625-630
50. Angotti LB, Post GR, Robinson NS, et al. Pancytopenia with myelodysplasia due to copper deficiency. Pediatric Blood Cancer. 2008;51:693-695
51. van den Heuvel-Eibrink MM. Paroxysmal nocturnal hemoglobinuria in children. Paediatr Drugs. 2007;9:11-16
52. Naseem S, Varma N, Trehan A. Primary/de novo paroxysmal nocturnal hemoglobinuria in a child from north India: A case report with review of literature. J Pediatr Hematol Oncol. 2009;31:274-276
53. van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al. Childhood paroxysmal nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol. 2005;128:571-577
54. Orazi A, Albitar M, Heerema NA, et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. Am J Clin Pathol. 1997;107: 268-274
55. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome. Blood. 2012;120:2454-2465
56. Hasle H, Baumann I, Bergstrasser E, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. 2004;18:2008-2014
57. Stary J, Locatelli F, Niemeyer CM. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant. 2005;35:S13-S16
58. Smith AR, Christiansen EC, Wagner JE, et al. Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. Pediatric Blood Cancer. 2013;60:705-710
59. Olnes MJ, Sloand EM. Targeting immune dysregulation in myelodysplastic syndromes. JAMA. 2011;305:814-819
60. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21: 1436-1441
61. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100:1570-1574
62. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26: 2505-2511
63. Yoshimi A, Baumann I, Führer M, et al. Immunosuppressive therapy with anti-Thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia. Haematologica. 2007;92:397-400
64. Hasegawa D, Manabe A, Yagasaki H, et al. Treatment of children with refractory anemia: The Japanese Childhood MDS Study Group trial (MDS99). Pediatric Blood Cancer. 2009; 53:1011-1015
65. Aalbers AM, van der Velden VHJ, Yoshimi A, et al. The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: A prospective study by EWOG-MDS. Leukemia. 2013. [Epub ahead of print].
66. George RE, Lahti JM, Adamson PC, et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A Children's Oncology Group study. Pediatric Blood Cancer. 2010;55: 629-638
67. Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009;113:2867-2868
68. Vidal DO, Paixao VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res. 2007;31: 175-181
69. Olk-Batz C, Poetsch AR, Nollke P, et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood. 2011;117:4871-4880